Mark Cuban Cost Plus Drug Co. has added Starjemza, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), to its portfolio.
The company, co-founded by billionaire entrepreneur Mark Cuban, is offering two strengths of the biosimilar at $360 per syringe, plus a $55 next-day refrigerated shipping cost. The retail price for the biosimilar is $3,632 at other pharmacies, according to Cost Plus Drugs’ website.
Stelara is approved to treat patients 6 years and older with plaque psoriasis or psoriatic arthritis, as well as adults with Crohn’s disease or ulcerative colitis. The brand-name biologic costs approximately $30,000, while the generic is about $7,200, according to GoodRx.
The biosimilar Starjemza, approved in May, has the same indications.
Read three other updates on Cost Plus Drugs here.
